Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1] Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false or misleading statements and failed to disclose critical information, including involvement in a fraudulent stock promotion scheme [1] - It is claimed that insiders used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [1] - Pomdoctor's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - As a result of these actions, the positive statements made by the defendants regarding the company's business and prospects were materially misleading [1] Group 2: Stock Price Decline - Pomdoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a drop of roughly $0.12 per share or approximately 24% in a single trading session [1] - This decline followed increased volatility and selling pressure amid broader investor concerns regarding Pomdoctor's financial performance and valuation [1] Group 3: Legal Proceedings - The court-appointed lead plaintiff will be the investor with the largest financial interest in the relief sought, who is also typical of class members [1] - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi, LLP encourages anyone with information regarding Pomdoctor's conduct to come forward, including whistleblowers and former employees [1]

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit social-media-based promotion scheme that created a buying frenzy among retail investors through sensational but baseless claims [3]. - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, but participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [5].